Patents Examined by Benet Prickril
  • Patent number: 5955432
    Abstract: Compounds of the formula ##STR1## and the esters, amides, amide/esters and salts thereof, wherein YCO is .gamma.-glu or .beta.-asp;G* is phenylglycine or glycine;Z is CH.sub.2, O or S; andX is a hydrocarbon radical selected from C.sub.6 -C.sub.8 alkyl or selected aromatic groupsare useful in modulating hematopoiesis in bone marrow, mitigating the bone-marrow-destructive effects of a chemotherapeutic agent, and in potentiating the toxicity of chemotherapeutic agents.
    Type: Grant
    Filed: July 3, 1996
    Date of Patent: September 21, 1999
    Assignee: Terrapin Technologies, Inc.
    Inventors: Lawrence M. Kauvar, Amy S. Morgan, Matthew H. Lyttle, Richard F. Borch
  • Patent number: 5863742
    Abstract: A method of inhibiting proteolytic degradation of a thermally-stable intracellular protein is described. The method involves adding 1 or more denaturing agents to a sample which contains the protease and the protein of interest and heating the resulting solution at a temperature and for period of time sufficient to denature the protease. The method optionally includes a step for lysing the cell if the protein of interest is contained in a cell in order to release said protein. Additionally, a method of determining Mx protein induced by interferon in a blood sample is described. The method involves adding to a blood sample a lysing agent, a denaturing agent, and a detergent selected to solubilize Mx protein. The sample containing Mx protein is then heated at a temperature of from about 50.degree. C. to about 60.degree. C. for a period of time of from about 1 minute to about 30 minutes, and the Mx protein in the solution then is determined.
    Type: Grant
    Filed: March 10, 1994
    Date of Patent: January 26, 1999
    Assignee: Chiron Diagnostics Corporation
    Inventors: Se-Kyung Oh, Harry Towbin
  • Patent number: 5814611
    Abstract: A pharmaceutical preparation for the therapy of immune deficiency conditions comprising an active principle--a peptide of the structure: H--L--Glu--L--Trp--OH and a pharmaceutically acceptable vehicle.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 29, 1998
    Assignee: Cytoven J.V.
    Inventors: Vyacheslav Grigorievich Morozov, Vladimir Khatskelevich Khavinson
  • Patent number: 5801225
    Abstract: Compounds useful as affinity chromatography supports and as labeled reagents are disclosed. The compounds are peptides which can be constituted in families of positively charged, negatively charged or uncharged small peptides or the amidated forms thereof with varying characteristics as to charge, charge distribution, hydrophobicity, cyclization, and helical conformation propensity.
    Type: Grant
    Filed: July 31, 1996
    Date of Patent: September 1, 1998
    Assignee: Terrapin Technologies, Inc.
    Inventor: Lawrence M. Kauvar
  • Patent number: 5795859
    Abstract: The present invention provides peptides which have the ability to abrogate TNF toxicity and/or LPS toxicity. The present invention further relates to compositions including these peptides as the active ingredient and methods of anti-inflammatory treatment involving the administration of this composition. The peptides of the present invention are based primarily on residue 1 to 26 of human TNF.
    Type: Grant
    Filed: March 15, 1994
    Date of Patent: August 18, 1998
    Assignee: Peptide Technology Limited
    Inventors: Deborah A. Rathjen, Fred Widmer, Geoffrey W. Grigg, Philip O. Mack
  • Patent number: 5786336
    Abstract: A method to potentiate the effect of a chemotherapeutic agent in a tumor cell, which method comprises administering to said tumor cell, along with said chemotherapeutic agent, a potentiating amount of a compound of the formula: ##STR1## or an amide, ester or hybrid amide/ester thereof, wherein X is a hydrocarbon radical optionally substituted on any aromatic moiety contained therein; Y--CO is .gamma.-Glu or .beta.-Asp and AA.sub.C is an amino acid, preferably glycine, phenylglycine, .beta.-alanine, alanine or phenylalanine is disclosed.Similar compounds can also be used to selectively exert cytotoxicity versus target cells as compared to nontarget cells and also to elevate the production of GM progenitors in bone marrow of mammalian subjects.
    Type: Grant
    Filed: September 19, 1994
    Date of Patent: July 28, 1998
    Assignee: Terrapin Technologies, Inc.
    Inventors: Lawrence M. Kauvar, Matthew H. Lyttle, Amy S. Morgan, Richard F. Borch
  • Patent number: 5767086
    Abstract: Compounds of the formula ##STR1## and the esters, amides, amide/esters and salts thereof, wherein YCO is .gamma.-glu or .beta.-asp;G* is phenyl glycine or glycine;Z is CH.sub.2, O or S; andX is a hydrocarbon radical of 1-20 C;are useful in stimulating the differentiation of bone marrow, mitigating the bone-marrow-destructive effects of a chemotherapeutic agent, and in potentiating the toxicity of chemotherapeutic agents.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 16, 1998
    Assignee: Terrapin Technologies, Inc.
    Inventors: Lawrence M. Kauvar, Matthew H. Lyttle, Amy S. Morgan, Richard F. Borch
  • Patent number: 5767087
    Abstract: A pharmaceutical preparation for the therapy of immune deficiency conditions comprising an active principle--a peptide of the structure: H-L-Glu-L-Trp-OH and a pharmaceutically acceptable vehicle.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 16, 1998
    Assignee: Cytoven J.V.
    Inventors: Vyacheslav G. Morozov, Vladimir K. Khavinson
  • Patent number: 5763394
    Abstract: A stable pharmaceutically acceptable aqueous formulation containing human growth hormone, a buffer, a non-ionic surfactant, and, optionally, a neutral salt, mannitol, or, a preservative, is disclosed. Also disclosed are associated means and methods for preparing, storing, and using such formulations.
    Type: Grant
    Filed: September 14, 1993
    Date of Patent: June 9, 1998
    Assignee: Genentech, Inc.
    Inventors: Barbara H. O'Connor, James Q. Oeswein
  • Patent number: 5739272
    Abstract: A procedure for obtaining carbocalcitonin comprising the condensation of fragment 1, a docosapeptide corresponding to the carboxamide end of the carbocalcitonin sequence, conveniently protected and anchored on resin, with fragment 2 or 3, a nonapeptide corresponding to the amino end of the salmon calcitonin sequence, with a ready-formed cycle between the Asu and Ser residua, and the treatment of the complete peptide skeleton (fragment 6 or 7) with an acid to free the totally deprotected peptide from the resin.
    Type: Grant
    Filed: February 3, 1994
    Date of Patent: April 14, 1998
    Assignee: Lipotec, S.A.
    Inventors: Marcos Canas Poblet, Berta Ponsati Obiols, Gemma Jodas Farres, David Andreu Martinez
  • Patent number: 5721212
    Abstract: Less toxic agents for reversal of heparin or low molecular weight heparin anticoagulation which are synthetic protamine-like polycationic peptides having a total cationic charge which is less than that of n-protamine. In preferred embodiments, arginine resides of n-protamine are replaced with lysine residues for ease of manufacture. Selective positively charged arginine residues have been replaced with an uncharged amino acid residue or its analog, such as glycine or glutamine, in order to reduce the total cationic charge on the polycationic peptide to the range of about ?+14! to ?+18!, preferably ?+16!. In specific embodiments, there are sequences of 29 amino acid residues wherein 4 to 5 clusters of 2 to 4 positively charged amino acids are separated by 2 to 6 neutral amino acids. The C-terminus and the N-terminus can be modified to mitigate against in vivo degradation by carboxypeptidases and aminopeptidases.
    Type: Grant
    Filed: July 9, 1996
    Date of Patent: February 24, 1998
    Assignee: University of Michigan, The Board of Regents . . . et al.
    Inventors: Thomas W. Wakefield, James C. Stanley, Philip C. Andrews
  • Patent number: 5716927
    Abstract: Human insulin analogues having a positively charged amino acid residue, i.e. Lys or Arg, in position B28, further being modified in the C-terminal end of the B-chain from Phe.sup.B24 to the C-terminal amino acid residue and wherein A18, A21 and/or B3 is different from Asn as well as insulin preparations containing the human insulin analogues are provided.
    Type: Grant
    Filed: September 21, 1995
    Date of Patent: February 10, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Per Balschmidt, Jens J.o slashed.rgen Veilgaard Brange
  • Patent number: 5716619
    Abstract: Antibody methods for blocking the effects of diabetes-associated peptide, or "amylin", a hormone found in the amyloid masses of Type 2 diabetics, are disclosed. This putative hormone has been discovered to function both to inhibit insulin secretion and to inhibit glycogen synthesis. Regulation is accomplished by blocking the binding of amylin or amylin agonists, including calcitonin gene related peptide (CGRP), or biologically active sub-peptides thereof. Inhibitors include antibodies directed to amylin and amylin agonist active sites. Other antagonists include anti-idiotype antibodies directed to antibodies directed to amylin.
    Type: Grant
    Filed: August 23, 1994
    Date of Patent: February 10, 1998
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventors: Garth J.S. Cooper, Howard Greene, Jr.
  • Patent number: 5714577
    Abstract: The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
    Type: Grant
    Filed: January 24, 1997
    Date of Patent: February 3, 1998
    Assignee: University of Pittsburgh
    Inventors: Ronald C. Montelaro, Sarah Burroughs Tencza, Timothy A. Mietzner
  • Patent number: 5708016
    Abstract: A compound of formula (I): ##STR1## in which: R.sub.1 represents an indolyl, naphthyl, tetrahydronaphthyl, thienyl, phenyl, optionally substituted, or (C.sub.3 -C.sub.7)cycloalkyl group,n represents an integer such that 1.ltoreq.n.ltoreq.8,m represents an integer such that 1.ltoreq.m.ltoreq.4,R.sub.2 represents an unsubstituted or substituted benzyl group, an unsubstituted or substituted phenyl group or a linear or branched (C.sub.1 -C.sub.6)alkyl group, its enantiomers, diastereoisomers and epimers as well as its addition salts with a pharmaceutically acceptable acid or base, and medicinal products containing the same are useful as substance P antagonists.
    Type: Grant
    Filed: February 14, 1997
    Date of Patent: January 13, 1998
    Assignee: Adir et Compagnie
    Inventors: Jean-Luc Fauchere, Nathalie Kucharczyk-Gentric, Emmanuel Canet, Michel Lonchampt
  • Patent number: 5705483
    Abstract: The present invention provides novel complexes consisting of certain GLP-1 molecules associated with a divalent metal cation that is capable of co-precipitating with a GLP-1 molecule. Pharmaceutical compositions and methods of using such complexes for enhancing the expression of insulin in B-type islet cells is claimed, as is a method for treating maturity onset diabetes mellitus in mammals, particularly humans.
    Type: Grant
    Filed: March 21, 1995
    Date of Patent: January 6, 1998
    Assignee: Eli Lilly and Company
    Inventors: John A. Galloway, James A. Hoffmann
  • Patent number: 5696001
    Abstract: The invention relates to fluorogenic compounds for the detection of hydrolyzing enzymes and the use of the fluorogenic compounds.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 9, 1997
    Assignee: Behringwerke Aktiengesellschaft
    Inventor: Klaus Habenstein
  • Patent number: 5693611
    Abstract: Provided are pharmaceutical formulations, and methods of inhibiting fungal and parasitic activity using a compound of formula I ##STR1## wherein: R', R", R'", R.sup.x1, R.sup.x2, R.sup.y1, R.sup.y2, R.sup.y3, R.sup.y4, and R.sup.0 are as defined herein below;R.sup.2 is a novel acyl side chain. Also provided are novel formulations and methods of inhibiting fungal and parasitic activity.
    Type: Grant
    Filed: January 17, 1997
    Date of Patent: December 2, 1997
    Assignee: Eli Lilly and Company
    Inventors: Stacy Kay Henle, William Wilson Turner
  • Patent number: 5688507
    Abstract: Thrombus or clot formation and accretion are inhibited by administering thrombin-displacing substances to a patient. The thrombin-displacing substances comprise either thrombin analogs which bind to the thrombin-binding site on fibrin or fibrin analogs which bind to a fibrin-binding site on thrombin. By displacing the thrombin from clot or thrombus, the thrombin is released into circulation where it is inactivated by endogenous anti-proteinases. The fibrin analogs which bind to the fibrin-binding site on thrombin may be linked to a second binding moiety which binds to and/or inactivates the catalytic site on thrombin to further inhibit thrombosis.
    Type: Grant
    Filed: November 13, 1995
    Date of Patent: November 18, 1997
    Assignee: Hamilton Civic Hospitals Research Development, Inc.
    Inventors: Jeffrey I. Weitz, Jack Hirsh
  • Patent number: 5688527
    Abstract: New lysine derivatives containing a fluoroalkyloxycarbonyl or fluoroalkylsulphonyl group of formula:COOH--CH(NH.sub.2)--(CH.sub.2).sub.4 --NH--X--(CH.sub.2).sub.n --Rin which n ranges from 0 and 4, X represents a divalent COO or SO.sub.2 group and R represents a linear or branched perfluoroalkyl radical having from 4 to 20 carbon atoms, salts thereof, and mixtures of the derivatives and the salts. A process for the preparation of these derivatives, salts, and mixtures and use of such derivatives, salts, and mixtures, especially in cosmetics. Compositions, especially cosmetic compositions, comprising the derivatives, salts, and mixtures.
    Type: Grant
    Filed: January 23, 1996
    Date of Patent: November 18, 1997
    Assignee: L'Oreal
    Inventors: Thierry Bordier, Michel Philippe